Joshua Mansour, M.D.
Hematologist-Oncologist
5 (42 RATINGS)
Clinical Expertise
CAR T Cell Therapy
Bone Marrow Transplantation
Stem Cell Transplantation
Appointments
Assistant Professor, Department Of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Los Angeles native Joshua Mansour, M.D., is committed to providing patients with the type of care he would want for his family. That means spending as much time as needed to answer all of their questions and working collaboratively with other experts across disciplines.
Dr. Mansour, who speaks Spanish fluently, completed his medical training at Ross University School of Medicine, where he received an Early Distinguished Career Award. He was an internal medicine resident at the Medical College of Georgia, an oncology/hematology fellow at the Medical University of South Carolina and a fellow in bone marrow transplantation and cellular therapy at Stanford University. Dr. Mansour has been recognized as a "40 Under 40 in Cancer," and his writing on medical issues has been published in U.S. News & World Report.
An avid fan of the Rams, Lakers and Dodgers, he enjoys surfing, snowboarding, running and hiking.
2018-present, American Board of Hematology
2018-present, American Board of Oncology
2015-present, American Board of Internal Medicine
2008-2012, Medical Degree, Ross University School of Medicine
2003-2007, Bachelor of Science, Vanderbilt University, College of Arts and Sciences, Nashville, TN
2005, Universidad Complutense, Madrid, Spain
2018-2019, Fellowship, Hematopoietic Stem Cell Transplantation & Cellular Immunotherapy, Stanford University, Palo Alto, CA
2015-2018, Fellowship in Hematology/Oncology, Medical University of South Carolina, Charleston, SC
2012-2015, Internal Medicine Residency, Medical College of Georgia, Augusta, GA
2019-present, Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2019-present, Associate Physician, Kaiser Permanente Medical Group, Bone Marrow Transplantation & Cellular Therapy, Los Angeles, CA
40 Under 40 in Cancer, Rising Stars & Emerging Leaders
Ross University School of Medicine 2019 Early Distinguished Career Award
Chancellor Scholar at Vanderbilt University
Superior Resident Achievement Award at Medical College of Georgia
Recognition for Commitment & Contribution to the Renaissance Research Program
California State Senate Award for Outstanding Contributions to the Local Environment
National Audubon Society Award for Taking Action to Preserve the Local Environment Through Leadership & Participation in the Community
Vice President, Medical Oncology Association of Southern California
American Society of Hematology
American Society of Clinical Oncology
American Society of Transplantation & Cellular Therapy
American Medical Association
Internal Medicine Association
American College of Physicians
Phi Delta Epsilon
Published Manuscripts
- “Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies.” Transplantation and Cellular Therapy. December 19, 2020. https://doi.org/10.1016/j.jtct.2020.12.020
- "Overall survival of patients with triple‐class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.” American Journal of Hematology. September 2020. https://doi.org/10.1002/ajh.26010 DOI: 10.1002/ajh.26010
- Gandhi, U, Cornell, RF, Lakshman, A, Gahvari, Z, McGehee, E, Jagosky, MH, Gupta, R, Varnado, W, Fiala, MA, Chhabra, S, Malek, E, Mansour, J, Paul, B, Barnstead, A, Kodali, S, Neppalli, A, Liedtke, M, Godby, KN, Kang, Y, Kansagra, A, Umyarova, E, Scott, EC, Hari, P, Vij, R, Usmani, SZ, Callander, NS, Kumar, SK, Costa, LJ “Outcomes of Patients with Multiple Myeloma Refractory to CD38 Targeted Monoclonal Antibody Therapy”. Leukemia. September 2019. doi: 10.1038/s41375-019-0435-7.
- Mansour, J, Rao, A, Shaheen, M, Yang, S, Ji-Hyun, L, Nordquist, H, Rixe, O. Increased bone remodeling on patients treated with a CTLA-4 inhibitor: First report of an unknown autoimmune reaction. Journal of Community and Supportive Oncology. August 2017. doi: https://doi.org/10.12788/jcso.0340
- Mansour, J, Brill, Mathew, Gourdin, Theodore “Rare Case of Spontaneous Tumor Lysis Syndrome (TLS) in a patient with Germ Cell Tumor (GCT): Literature Review and Approach to Management”. MOJ Clinical Med Case Rep. July 2017. DOI: 10.15406/mojcr.2017.07.00190
- Mansour, J, Mangaonkar, Kota, V. “Recurrent Metastatic Parotid Carcinosarcoma in an Asymptomatic Patient”. Journal of Investigative Medicine High Impact Case Reports. 2016 Nov 4;4(4):2324709616676590
- Mangaonkar, A, Xu, H, Mondal, A, Mansour, J, DeRemer, D, Clemmons, A, Chintalapally, R, Jillella, A, Kolhe, R, Kota, V. “Prognostic value of complete remission with superior platelet counts in Acute Myeloid Leukemia. Journal of Community and Supportive Oncology. 2016 Feb;14(2):66-71. doi: 10.12788/jcso.0231
- Mansour, J, Mangaonkar, A, Keen, R, Kukkadapu, T, Chintallapally, R, Kota, V. “Pneumatosis Intestinalis in an Acute Promyelocytic Leukemia (APL) patient”. Case Reports in Hematology. October 2015. 2015;2015:576042. doi: 10.1155/2015/576042. Epub 2015 Oct 8
- Kolhe, R, Mangaonkar, A, Mansour, J, Clemmons, A, Shaw, J, Dupont, B, Walczak, L, Mondal A, Rojiani, A, Jillela, A,Kota, V, “Utility and impact of early t(15;17) identification by Fluorescence In-Situ Hybridization (FISH) in clinical decision making for patients in Acute Promyelocytic Leukemia (APL)”. Int J Lab Hematol. 2015 Aug; 37(4):515-20. doi: 10.1111/ijlh.12326. Epub 2015 Jan 14.
- Mangaonkar, A, Mansour, J, Clemmons, A, Kolhe, Jillella, A, Kota, V. "Prognostic Value of Day 30 Platelet Count After First Induction Cycle in Acute Myeloid Leukemia.". Journal of Community and Supportive Oncology. October 2015.
- Kota, V, Clemmons, A, Mansour, J, Chand, A, Simmons, J, Kolhe, R, Awan, F, Jillella, A. “ Congestive Heart Failure during induction with Anthracycline based therapy in patients with Acute Promyelocytic Leukemia may be more frequent than expected”. J Community Support Oncol. 2014 Nov;12(11):390-3. doi: 10.12788/jcso.0084.
- Zakharia, Y, Mansour, J, Vasireddi, S, Fatakhov, E, Koch, C, Hrinczenko, B. “Tumor Lysis Syndrome in Retroperitoneal Sarcoma” . Journal of Investigative Medicine High Impact Case Reports.. 2014 Jul-Sep; 2(3): 2324709614542340. Published online 2014 Jul 4. doi: 10.1177/2324709614542340
- Mansour, J, Fields, B, Macomson, S, Rixe, O. “Significant Anti-tumor Effect of Bevacizumab in Treatment of Pineal Gland Glioblastoma Multiforme”. Targeted Oncology. 2014 Dec;9(4):395-8. doi: 10.1007/s11523-014-0327-8. Epub 2014 Jul 8.
Abstracts
- Gandhi, U, Cornell RF, Lakshman A, Gahvari Z, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ. “Natural History of Patients with Multiple Myeloma Refractory to Elotuzumab and Outcomes of Subsequent Therapy with Anti-CD38 Monoclonal Antibodies.” Abstract # 112246. Poster Presentation. American Society of Hematology. December 2, 2018. San Diego Convention Center, Hall GH. Blood 2018 132:3303; doi: https://doi.org/10.1182/blood-2018-99-112246
- Gandhi U, Cornell RF, Lakshman A, Gahvari Z, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ “Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment.” Abstract # 111033. Poster Presentation. American Society of Hematology. December 2, 2018. San Diego Convention Center, Hall GH. Blood 2018 132:3233; doi: https://doi.org/10.1182/blood-2018-99-111033
- Gandhi U, Cornell RF, Lakshman A, Gahvari Z, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ. “Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Treatment.” Abstract # 115078. Poster Presentation. American Society of Hematology. December 1, 2018. San Diego Convention Center, Hall GH. Blood 2018 132:2015; doi: https://doi.org/10.1182/blood-2018-99-115078
- Mansour J, Rao A, Shaheen M, Yang S, Ji-Hyun L, Nordquist H, Rixe O. “Increased bone remodeling on patients treated with a CTLA-4 inhibitor: First report of an unknown autoimmune reaction.” J Clin Oncol 33. June 2015 (suppl; abstr e14027).
- Mangaonkar A, Mohsin J, Mansour J, Kolhe R, Mondal A, Puttagunta H, Jillella A, Kota V. “Day 30 Platelet Count as a Prognostic Marker of Survival in Acute Myeloid Leukemia.” Blood 124 (21). December 2014.
- Mansour J, Mangaonkar A, Zakharia Y, Chand A, Jillella A, Kota V. “Utility of D-Dimer As a Marker for Diffrentiation Syndrome and Infections in Acute Promyelocytic Leukemia (APL)”. Abstract # 65814 Publication # 4986. Blood. November 2013.
- Zakharia Y, Kota V, Mansour J, Prabhakar R, Lan L, Awan F, Jillella A. “Serum Alkaline Phosphatase Level on Day 4 of G-CSF Administration Could Be a Simple Yet Practical Surrogate Marker for CD34 Mobilization and Collection.” Abstract # 65543 Publication # 4519. Blood. November, 2013.
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with 5 stars being the highest.
Ratings
5.0
Recommend this provider office
5.0
Provider listen carefully to you
5.0
Know important info medical history
5.0
Show respect for what you say
4.9
Spend enough time with you
4.9
Provider explain in way you understand
4.8
Rate provider 0-10
Reviews
11/29/22
Again, I hope that I never had to recommend anyone else to City of Hope, however, I know they will be well cared for by COH. - Verified patient
11/29/22
Dr. Mansour was excellent. He explained everything in detail, yet in simple enough terms that the average person could understand. He repeated certain parts slowly so that I could write everything down and have a way to remember things after the appointment. My partner and I went into this appointment with a long list of questions & concerns and feeling quite uncertain; we left feeling reassured that Dr. Mansour and the nurse coordinator had everything under control. While I hope I never have to recommend Dr. Mansour to a friend/family member, I know they would be in good hands with him. - Verified patient
07/07/22
The doctor made me feel apart of my own health explaining things throughly and always made time for me - Verified patient
03/18/22
Dr Mansour is super wonderful - Verified patient
01/30/22
I am a stem cell donor for my sister and the City of Hope hospital appears to be very organized and the staff appear to be very caring - Verified patient